You have no items in your shopping cart.
You have no items in your shopping cart.
Catalog Number | orb758786 |
---|---|
Category | Antibodies |
Description | Rabbit monoclonal antibody to CTLA4 |
Species/Host | Hamster |
Clonality | Monoclonal |
Clone Number | 9H10 |
Tested applications | ELISA, FC, WB |
Reactivity | Mouse |
Isotype | IgG |
Immunogen | This antibody was raised by immunising Syrian hamsters with Staphylococcus A bacteria coated in CTLA-4, isolating B cells from the immunised hamsters and fusing these with the P3X3.Ag8.653 myeloma line to produce stable hybridomas. |
Concentration | 1 mg/ml |
Purity | Purified |
Conjugation | Unconjugated |
Target | CTLA-4 |
UniProt ID | P09793 |
Storage | Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C. |
Buffer/Preservatives | PBS with 0.02% Proclin 300. |
Alternative names | CD152; CTLA4; cytotoxic T-lymphocyte-associated an Read more... |
Note | For research use only |
Application notes | CTLA-4 is upregulated on T cells following their activation, and acts as a negative regulator of T cell responses; CTLA-4 binds to the B7 molecules CD80 and 86, resulting in the delivery of an inhibitory signal, and consequent downregulation of T cell-mediated immunity. Administration of 9H10 blocks the interaction between CTLA-4 on the T cell surface and CD80 and CD86. This promotes the activation of effector T cells and stimulates the immune response raised against weak antigens, including tumour antigens. While this antibody alone does not enhance T cell proliferation, it does significantly increase T cell proliferation when administered together with anti-CD28 (clone 37.51) (Krummel & Allison, 1995), anti-OX40 and anti-GITR (Houot & Levy, 2009). Blocking CTLA-4 induces T cell anti-tumour immunity in animal models, both by suppressing regulatory T cell activity and directly promoting CD8+ T cell effector function (Peggs et al, 2009). In transgenic murine models of prostate cancer, the use of a CTLA-4 blockade in conjunction with an irradiated tumour cell vaccine stimulates an immune response against primary tumours, and results in a significant reduction in tumour incidence (Hurwitz et al, 2000). Similarly, in murine melanoma models, CTLA-4 blockage, in combination with CD40 stimulation and adenoviral vaccination, can elicit complete regression (Sorensen et al, 2010). In murine models of pancreatic ductal adenocarcinoma, 9H10 has also been shown to induce T cell-dependent tumour regressions (Vonderheide et al, 2015). Priming the T cell response with CD40 mAbs or chemotherapy reversed the resistance to 9H10 and RMP1-14 observed in well-established tumours. Additionally, this antibody has been used to detect CTLA-4 using ELISA (Krummel & Allison, 1995) and to stain CTLA-4-expressing cells (Deeths et al, 1999). |
Expiration Date | 12 months from date of receipt. |
ELISA, FACS, IF, IHC-P, WB | |
Human | |
Mouse | |
Monoclonal | |
Unconjugated |
Filter by Rating